American Society of Hematology

ASH Scholar Award Support Information

ASH Scholar Awards are limited to a maximum of $100,000 for fellow scholars and $150,000 for junior faculty scholars over a two- to three-year period, with an annual maximum of $50,000 for fellows and $75,000 for junior faculty. Up to 15 percent of the award can be (but is not required to be) used for benefits, including medical and dental insurance, life insurance, and retirement benefits.

All awards are activated on July 1 of the following year. The applicant has the option of concluding the award on June 30, two or three years after activation. All award payments are made on a quarterly basis - the amount depends on whether the award is being spread over two or three years. Payments are made to the appropriate financial officer of the institution as indicated on the proposed budget within the full application.

Research Supported

Basic/Translational Research:

  • Basic Research:
    ASH considers basic research to include a broad spectrum of studies on genes, proteins, lipids, carbohydrates, biochemical and signaling pathways, receptors, cells and animals, as well as samples obtained from humans, all of which are designed to further our understanding of the blood, bone marrow, and related organs or the pathogenesis of blood disorders. The emphasis for grants in this category should be on the discovery of new knowledge in a traditional laboratory setting.
  • Translational Research:
    ASH defines translational research as using knowledge of human biology to develop and test the feasibility of relevant interventions in humans and/or determine the biological basis for observations made in individuals with hematologic conditions or in populations at risk. Translational research should be founded on and directly connected to some aspect of human biology and may encompass any form of structural, biochemical, genetic, or other appropriate experimental approaches using human materials. The proposal should address clinical applications - not just test development - although the development of novel instrumentation of value to hematology is clearly within the scope of the application. Clinical trial projects with laboratory correlatives are considered clinical.

Clinical Research: ASH considers clinical/translational research to include patient-oriented research and outcomes-based research. ASH emphasizes that clinical research must involve substantial interaction with patients.

  • Patient-Oriented Research
    For the purposes of the ASH Scholar Awards program, patient-oriented research is defined as research conducted with human subjects and involves an investigator directly interacting with human subjects. Categories of patient-oriented research include: 1) mechanisms of human disease, 2) therapeutic interventions, 3) clinical trials, and 4) development of new technologies.
  • Outcomes-Based Research
    ASH strongly encourages applications in outcomes-based research. Options for outcomes-based research include: 1) a decision-analysis or cost-effectiveness analysis of a relevant topic within hematology, 2) survey-based research investigating practice patterns, access to care, quality of care, clinical outcomes, or quality of life among patients with hematologic conditions, 3) retrospective analyses of large administrative databases (e.g., CMS, a large insurer, SEER) that may enlighten health care policy decisions related to hematologic disease, and 4) large scale epidemiologic or genetic epidemiologic studies that define the incidence, prevalence, prognosis, and natural history or the effects of therapy of blood disorders.

Applications that fall within any of the categories discussed above are encouraged.

Related Items

back to top